Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast Cancer

Release Date: December 31, 2018
Expiration Date: December 31, 2019
Media: Internet - based

Activity Overview

We are pleased to present this CME-certified activity, a PER® Live Tumor Board titled Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast Cancer – Enduring CME Activity. This activity is an enduring version of the live Tumor Board originally presented by PER® at on December 12, 2018, at 3:00 PM EST.

This program will update oncology healthcare professionals who participate in the multidisciplinary treatment of patients with estrogen receptor–positive (ER+) metastatic breast cancer (MBC) by providing expert guidance, interpretation, and insight on the importance and impact of CDK4/6 inhibitor therapy. Unfortunately, current understanding of how to utilize CDK4/6 inhibitors is generally limited to registrational studies.

Retroactive observational studies on real-world populations will aid clinicians in understanding how concepts such as dose adjustments and adverse event management are performed in patient populations that were not a part of the original clinical trials that drug approvals were based on. This activity will incorporate recent real-world data to ensure that clinicians maintain state-of-the-art treatment practices.

Benefits of Participating

  • Apply novel management strategies to your practice to improve patient outcomes
  • Participate in an exciting case-based format about current challenges and controversies in the treatment of ER+ breast cancer
  • Incorporate evolving treatment paradigms in the setting of ER+ breast cancer
  • Update your clinical decision-making based upon individual patient/tumor characteristics

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Evaluate results from studies of CDK4/6 inhibitor therapies for the treatment of metastatic breast cancer (MBC), including evidence generated from randomized clinical trials and real-world data analyses
  • Integrate evidence from clinically relevant randomized trials and real-world data analyses of CDK4/6 inhibitor therapies for MBC into existing and emerging management strategies
  • Incorporate key insights and strategies derived from real-world evidence into the mitigation and management of predictable treatment-related toxicities in the management of MBC

Faculty, Staff, and Planners' Disclosures


Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant/Research Support: Research support for clinical trials through the University of California from Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Plexxikon, Odonate, Daiichi Sankyo, Eisai, MacroGenics; Consultant (Honorarium): Celltrion


Angela DeMichele, MD, MSCE
Alan and Jill Miller Endowed Chair in Breast Cancer Excellence
Professor of Medicine and Epidemiology
Co-Leader, Breast Cancer Research Program
Abramson Cancer Center Senior Scholar
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania School of Medicine
Philadelphia, PA

Disclosures: Grant/Research Support: Genentech, Pfizer, Novartis, Menarini; Consultant: Pfizer

Komal Jhaveri, MD, FACP
Attending, Breast Medicine Service and Early Drug Development Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Pfizer, Genentech, Novartis, Novita Pharmaceuticals, Debiopharm, Menarini; Consultant: Novartis, Pfizer, AstraZeneca, BMS, Taiho Oncology, Jounce Therapeutics, Spectrum Pharmaceuticals, ADC Therapeutics

Joseph A. Sparano, MD
Professor of Medicine & Women's Health
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

Disclosures: Grant/Research Support: Deciphera, Prescient; Consultant: Roche/Genentech, Eli Lilly, AstraZeneca, Celldex, Juno, Pfizer; Stock/Shareholder: MetaStat

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields

Become a Member

Forgot Password?
Calendar of Events
Filter By